Nikolova, Dafina
Preferred name
Nikolova, Dafina
Official Name
Nikolova, Dafina
Main Affiliation
Email
dafina.nikolova@medf.ukim.edu.mk
38 results
Now showing 1 - 10 of 38
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Tumour Lymphocytic Infiltration, Its Structure and Influence in Colorectal Cancer Progression(Scientific Foundation Spiroski, 2018); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Unrecognized Wernicke's encephalopathy during pregnancy induced by hyperemesis gravidarum(Termedia Publishing House Ltd., 2025); ; ; Hyperemesis gravidarum (HG) is the most common indication for hospitalization in the first half of pregnancy. Although 70—90% of pregnant women experience nausea and vomiting, few develop HG. Maternal complications include malnutrition and vitamin deficiencies, peripheral neuropathy, and serious neurological complications, including central pontine myelinolysis and Wernicke’s encephalopathy (WE). - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Tertiary Lymphoid Structures in Colorectal Cancers and Their Prognostic Value(ID Design 2012/DOOEL Skopje, 2018-10-25); ; ; Hadzi-Manchev, DraganTumor-infiltrating lymphocytes (TIL) in tumour stroma are considered to be involved in the elimination of malignant cells and prevention of metastasis formation. TIL consist of T lymphocytes including cytotoxic lymphocytes that are a constituent part of the effector mechanism of anti-tumour immunity and B lymphocytes that can form tertiary lymphoid structures (TLS). TLS has been described in several solid tumours and colorectal carcinoma (CRC), and the influence on the local and systemic anti-cancer response. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, TP53 Mutation in Correlation to Immunohistochemical Expression of P53 Protein in Patients with Hepatocellular Carcinoma(ID Design 2012/DOOEL Skopje, 2018-07-20); ; ; BACKGROUND: Mutations causing p53 inactivation are among the most common genetic alterations in human malignant tumours including hepatocellular carcinoma. Detection of p53 gene mutations in patients with hepatocellular carcinoma (HCC) should provide relevant data for the patients from the Republic of Macedonia and should allow the survivals additional therapeutic option as is gene therapy. AIM: We aimed to detect p53 gene mutations in HCC tissue, and to correlate them with the immunoexpression of p53 protein and multiple clinicopathologic characteristics of a tumour. MATERIAL AND METHODS: We analysed thirty patients with HCC for multiple clinic-pathological characteristics. Tumour tissue samples were immunostained for p53 and detection of p53 gene mutations was performed by polymerase chain reaction followed by Sanger sequencing. RESULTS: Changes in p53 gene sequence were detected in four patients (13.33%), one of them a polymorphism and the other three were missense point mutations with p53 immunoexpression of 50%, 0%, 0% and 90%, respectively. All patients with p53 mutations had cirrhosis. Two of them had Hepatitis B infection, moderately differentiated tumour and T2 status. There was one case with a well-differentiated tumour and one with T4 status. All of them were with vascular invasion. The size of the tumours was in the range of 2.5 cm to 16 cm. All 3 mutations were located in exon 7. CONCLUSION: Mutations in p53 gene are not always associated with obviously altered immunoexpression of p53 protein. Detection of p53 gene mutations is necessary in each case because the new therapeutic modalities offer to apply gene therapy. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Evaluation of the Effects of Gastro Protect as an Alternative Medicine on Gastritis and Other Gastrointestinal Symptoms(Macedonian Academy of Sciences and Arts, 2024-03-01); ; ; ; Introduction: The use of herbal medicine as a part of the Complementary and Alternative Medicine is increasing worldwide. Herbal remedies are used to better different conditions including gastritis. Material and Methods: We conducted a prospective randomized control clinical trial on a total sample of 72 patients with gastritis in order to examine the effects of the commercial herbal product Gastro Protect. After 6 weeks of conventional therapy the patients were divided into two groups with 36 patients each. As a continuation of the treatment, Group 1 received conventional therapy + Gastro Protect and Group 2 received conventional therapy + Placebo. We analyzed 14 selected gastrointestinal symptoms, five related to digestive problems, and nine related to stool and bowel problems. For assessing the selected symptoms we used seven point gastrointestinal symptom rating scale (GSRS). Results: The Gastro Protect group had a significantly lower GSRS score (better condition) compared to the Placebo group related to all five selected symptoms of digestive problems as: abdominal pain (p=0.0250), hunger pain (p=0.0276), nausea (p=0.0019), heartburn (p=0.00001), and acid reflux (p=0.0017). The Gastro Protect group, also had a significantly lower GSRS score (better condition) compared to the Placebo group related to three out of nine selected bowel symptoms: rumbling (p=0.0022), abdominal distension (p=0.0029), and gas or flatus (p=0.0039). Conclusion: Gastro protect was effective in treating gastritis and other gastrointestinal symptoms. It was safe for usage and showed almost no side effects. In our study, Gastro Protect reduced the examined gastric symptoms and related examined intestinal symptoms. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hepatocellular carcinoma - clinicopathological characteristics, survival, and expression of various histologic molecular markers(Termedia Sp. z.o.o., 2019); ; The aim of this study was to make a clinical characterisation of patients with hepatocellular carcinoma and to investigate the expression of a set of molecular markers in patients from the Republic of North Macedonia. We analysed 60 patients for clinicopathologic factors, and we investigated tumour tissue and surrounding liver tissue for immunoexpression of E-cadherin, β-catenin, cyclin D1, and p53. Infection with hepatitis virus B and C (p < 0.001), tumour dimension (p < 0.001), vascular invasion (p < 0.002), and tumour differentiation (p < 0.021) significantly influenced the survival of the patients. E-cadherin and β-catenin expression reduction and cyclin D1 and p53 overexpression were significantly higher in the tumour than in the non-tumour tissue (p < 0.001; p < 0.001; p = 0.001; p < 0.001, respectively). No significant correlation was found between clinicopathological characteristics and the analysed molecules nor between the molecules themselves. The immunoexpression of E-cadherin, β-catenin, cyclin D1, and p53 was not related to the tumour aggressiveness and prognosis. However, their significantly higher expression in HCC tissue compared to that in non-tumour tissue indicate their important role in hepatocarcinogenesis. The clinicopathological characteristics of the neoplasm remain highly predictive factors for the survival of the patients. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Biologic Therapy in Inflammatory Bowel Disease - Results from a Single Tertiary Care Center in North Macedonia(Македонска академија на науките и уметностите, Одделение за медицински науки = Macedonian Academy of Sciences and Arts, Section of Medical Sciences/Walter de Gruyter GmbH, 2023-07-01); ; ; ; Medical therapies used for Inflammatory Bowel Disease (IBD) include conventional (e.g. 5-aminosalicylates, steroids, immunomodulators) and biologic (e.g. inhibitors of tumor necrosis factor - alpha, integrin inhibitors, interleukin inhibitors) medications. Biologics, due to their high cost, were unfortunately not covered by the public health insurance system in North Macedonia until 2019 and, therefore, not widely utilized for our IBD patients. In 2019, the University Clinic of Gastroenterology and Hepatology in Skopje developed a biologic therapy supply, provided by the National Health Insurance Fund, making this therapy available for a larger number of patients. This report presents the initial results of our prospective, single tertiary-care center study on the effects of biologic therapy in patients with IBD in North Macedonia. The study is focused on the evaluation of clinical outcomes after anti-tumor necrosis factor alpha (anti TNF-alpha) therapy in IBD patients with prior inadequate response to conventional medications. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Osseous Metaplasia un Ovarian Endometrial Cyst: A Case Report(2019); ; Pandilov, StefanOsseous metaplasia in the female genital tract is a rare condition with unknown clinical importance and unknown etiology. We report a rare case of osseous metaplasia in an ovarian endometrial cyst, and comment to a chronic inflammation as a possible etiology - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Advancing the global public health agenda for NAFLD: a consensus statement(Springer Science and Business Media LLC, 2022) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, MANAGEMENT OF CHOLANGIOHYDATIDOSIS WITH ENDOSCOPIC RETROGRADE CHOLANGIOGRAPHY(European Society of Gastrointestinal Endoscopy, 2022); ; ;